Literature DB >> 21812057

Characterization of N-cadherin unbinding properties in non-malignant (HCV29) and malignant (T24) bladder cells.

Małgorzata Lekka1, Dorota Gil, Wojciech Dąbroś, Justyna Jaczewska, Andrzej J Kulik, Janusz Lekki, Zbigniew Stachura, Jerzy Stachura, Piotr Laidler.   

Abstract

The expression of N-cadherin, characteristic of various cancers, very often leads to changes in the cells' adhesive properties. Thus, we sought to find out if N-cadherin expressed in various, but cancer-related cells, differs in its functional properties that could contribute to variations in cells' phenotypes. In our work, measurements of an unbinding force of a single N-cadherin molecule, probed with the same antibody both on a surface of living non-malignant (HCV29) and malignant cells (T24) of bladder cancer, were carried out with the use of an atomic force microscopy. The results show the enhanced N-cadherin level in T24 malignant cells (8.7% vs. 3.6% obtained for non-malignant one), confirmed by the Western blot and the immunohistochemical staining. The effect was accompanied by changes in unbinding properties of an individual N-cadherin molecule. Lower unbinding force values (26.1 ± 7.1 pN) in non-malignant cells reveal less stable N-cadherin complexes, as compared to malignant cells (61.7 ± 14.6 pN). This suggests the cancer-related changes in a structure of the binding site of the antibody, located at the extracellular domain of N-cadherin.
Copyright © 2011 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21812057     DOI: 10.1002/jmr.1123

Source DB:  PubMed          Journal:  J Mol Recognit        ISSN: 0952-3499            Impact factor:   2.137


  2 in total

1.  Atomic force microscopy reveals a role for endothelial cell ICAM-1 expression in bladder cancer cell adherence.

Authors:  Valérie M Laurent; Alain Duperray; Vinoth Sundar Rajan; Claude Verdier
Journal:  PLoS One       Date:  2014-05-23       Impact factor: 3.240

2.  The softening of human bladder cancer cells happens at an early stage of the malignancy process.

Authors:  Jorge R Ramos; Joanna Pabijan; Ricardo Garcia; Malgorzata Lekka
Journal:  Beilstein J Nanotechnol       Date:  2014-04-10       Impact factor: 3.649

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.